SCHEMBL8255373

SCHEMBL8255373

N#CCc1c2c(cc3c1CCC3)CCC2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ KDM4E B2RXH2 4/20 0.32
▸ NLRP3 Q96P20 4/20 0.32
▸ HTT P42858 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HIF1A Q16665 1/20 0.31
▸ ATM Q13315 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ APOBEC3G Q9HC16 1/20 0.30
▸ XDH P47989 1/20 0.30
▸ SLC22A12 Q96S37 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8254446 0.96 MAPT (0.37) MAPTLMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL25837417 0.71 KDM4E (0.37) MAPTSMN1; SMN2ALDH1A1KDM4ENLRP3
SCHEMBL20713668 0.71 MAPT (0.47) MAPTLMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL8255294 0.71 LMNA (0.49) MAPTLMNASMN1; SMN2ALDH1A1NLRP3
SCHEMBL8249619 0.71 ALDH1A1 (0.33) MAPTALDH1A1TSHR
SCHEMBL8250620 0.71 ALDH1A1 (0.31) ALDH1A1KDM4ETSHR
SCHEMBL10741466 0.70 SMN1; SMN2 (0.37) LMNASMN1; SMN2ALDH1A1KDM4EHTT
SCHEMBL10752394 0.68 MEN1 (0.37) ALDH1A1KDM4EHTTTSHRHSD17B10
SCHEMBL10750796 0.68 KDM4E (0.33) MAPTSMN1; SMN2ALDH1A1KDM4EHTT
SCHEMBL24960169 0.68 MAPT (0.45) MAPTLMNASMN1; SMN2ALDH1A1NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 — — US disclosed
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 — — US disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 — — US disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 — — US disclosed
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-01-14 — — US disclosed
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-01-14 — — US disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
WO-2006116157-A9 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS INC (US) 2007-03-01 — — WO disclosed
WO-2006116157-A2 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2006-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, DPP3, DPP7 MAPT 3665/4885LMNA 4383/4885SMN1; SMN2 3639/4885
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP7 MAPT 3665/4885LMNA 4383/4885SMN1; SMN2 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback